Trident Lifeline Ltd
TLLTrident Lifeline Ltd
TLLPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
42.22 | 6.44 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Trident Lifeline Limited is engaged in the pharmaceutical business ethical marketing in domestic as well as international market. The Company is also engaged in distribution of pharmaceutical products through a third party distribution network. It offers a range of pharmaceutical formulations and products manufactured on contract manufacturing under loan license. It deals in capsules, tablets, liquid ointment, gel, ice gel, mouthwash, paste, solution, suspension, dry powders and toothpaste. Its product portfolio includes a range of drugs like Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozoal, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nutraceutical and Non-steroidal anti-inflammatory drug (NSAIDS). Its product portfolio consists of approximately 832 products. It operates in India, as well as African, Latin American and East Indian countries.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2022 | FY 2023 | FY 2024 | TTM | ||||
---|---|---|---|---|---|---|---|---|
Total Revenue | 22.37 | 32.85 | 46.71 | 57.71 | ||||
Raw Materials | 14.69 | 23.12 | 30.58 | 43.88 | ||||
Power & Fuel Cost | 0.02 | 0.10 | 0.26 | |||||
Employee Cost | 1.10 | 1.39 | 1.92 | |||||
Selling & Administrative Expenses | 0.94 | 1.39 | 1.97 | |||||
Operating & Other expenses | 2.31 | -0.56 | 1.67 | |||||
EBITDA | 3.31 | 7.41 | 10.31 | 13.83 | ||||
Depreciation/Amortization | 0.20 | 0.36 | 0.97 | 1.37 | ||||
PBIT | 3.11 | 7.05 | 9.34 | 12.46 | ||||
Interest & Other Items | 0.13 | 0.48 | 0.65 | 1.39 | ||||
PBT | 2.98 | 6.57 | 8.69 | 11.07 | ||||
Taxes & Other Items | -0.96 | 0.56 | 2.35 | 2.84 | ||||
Net Income | 3.94 | 6.01 | 6.34 | 8.23 | ||||
EPS | 4.93 | 6.16 | 5.51 | 7.16 | ||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | ||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Trident Lifeline Ltd | 54.81 | 6.44 | — |
Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
Cipla Ltd | 31.21 | 4.80 | 0.82% |
Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare TLL with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
TLL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Net profit of Trident Lifeline rose 98.25% to Rs 3.39 crore in the quarter ended September 2024 as against Rs 1.71 crore during the previous quarter ended September 2023. Sales rose 57.70% to Rs 15.66 crore in the quarter ended September 2024 as against Rs 9.93 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales15.669.93 58 OPM %28.2222.16 - PBDT4.672.47 89 PBT4.512.31 95 NP3.391.71 98 Powered by Capital Market - Live
Trident Lifeline will hold a meeting of the Board of Directors of the Company on 19 October 2024.Powered by Capital Market - Live
Trident Lifeline announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 4.49%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant